Novel detection assay by PCR-RFLP and frequency of the CYP3A5 SNPs, CYP3A5*3 and *6, in a Japanese population

被引:165
作者
Fukuen, S
Fukuda, T
Maune, H
Ikenaga, Y
Yamamoto, I
Inaba, T
Azuma, J
机构
[1] Osaka Univ, Grad Sch Pharmaceut Sci, Suita, Osaka 5650871, Japan
[2] Org Pharmaceut Safety & Res, Tokyo, Japan
[3] Univ Toronto, Fac Med, Dept Pharmacol, Toronto, ON M5S 1A8, Canada
来源
PHARMACOGENETICS | 2002年 / 12卷 / 04期
关键词
CYP3A5; single nucleotide polymorphism (SNP); PCR-RFLP; Japanese;
D O I
10.1097/00008571-200206000-00009
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
In this study, we established useful and reliable methods for the direct detection of the variants of CYP3A5 gene by polymerase chain reaction (PCR) and Ddel restriction analysis. The frequency of CYP3A5 related SNPs in 200 healthy Japanese male subjects was determined. The homozygous wild-type (*1/*1) frequency was 7.0% (14/ 200), the heterozygous (*1/*3) frequency was 32.5% (65/ 200) and the homozygous mutant-type (*3/*3) frequency was 60.5% (121/200). The *6 allele was not detected in any of the Japanese individuals. This result suggests that an estimated 40% of the Japanese express relatively high levels of metabolically active CYP3A5 protein. The proposed detection assays are useful for screening the CYP3A5 related SNPs in pharmacogenetic research.
引用
收藏
页码:331 / 334
页数:4
相关论文
共 10 条
[1]  
AOYAMA T, 1989, J BIOL CHEM, V264, P10388
[2]   cDNA cloning and initial characterization of CYP3A43, a novel human cytochrome p450 [J].
Domanski, TL ;
Finta, C ;
Halpert, JR ;
Zaphiropoulos, PG .
MOLECULAR PHARMACOLOGY, 2001, 59 (02) :386-392
[3]   Genomic organization of the human CYP3A locus:: identification of a new, inducible CYP3A gene [J].
Gellner, K ;
Eiselt, R ;
Hustert, E ;
Arnold, H ;
Koch, I ;
Haberl, M ;
Deglmann, CJ ;
Burk, O ;
Buntefuss, D ;
Escher, S ;
Bishop, C ;
Koebe, HG ;
Brinkmann, U ;
Klenk, HP ;
Kleine, K ;
Meyer, UA ;
Wojnowski, L .
PHARMACOGENETICS, 2001, 11 (02) :111-121
[4]  
GORSKI JC, 1994, BIOCHEM PHARMACOL, V47, P1643
[5]   Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression [J].
Kuehl, P ;
Zhang, J ;
Lin, Y ;
Lamba, J ;
Assem, M ;
Schuetz, J ;
Watkins, PB ;
Daly, A ;
Wrighton, SA ;
Hall, SD ;
Maurel, P ;
Relling, M ;
Brimer, C ;
Yasuda, K ;
Venkataramanan, R ;
Strom, S ;
Thummel, K ;
Boguski, MS ;
Schuetz, E .
NATURE GENETICS, 2001, 27 (04) :383-391
[6]   Evaluation of the genetic component of variability in CYP3A4 activity:: a repeated drug administration method [J].
Özdemir, V ;
Kalow, W ;
Tang, BK ;
Paterson, AD ;
Walker, SE ;
Endrenyi, L ;
Kashuba, ADM .
PHARMACOGENETICS, 2000, 10 (05) :373-388
[7]  
SHIMADA T, 1994, J PHARMACOL EXP THER, V270, P414
[8]   No ethnic difference between Caucasian and Japanese hepatic samples in the expression frequency of CYP3A5 and CYP3A7 proteins [J].
Tateishi, T ;
Watanabe, M ;
Moriya, H ;
Yamaguchi, S ;
Sato, T ;
Kobayashi, S .
BIOCHEMICAL PHARMACOLOGY, 1999, 57 (08) :935-939
[9]   In vitro and in vivo drug interactions involving human CYP3A [J].
Thummel, KE ;
Wilkinson, GR .
ANNUAL REVIEW OF PHARMACOLOGY AND TOXICOLOGY, 1998, 38 :389-430
[10]   Ethnic differences in drug disposition and response [J].
Wood, AJJ .
THERAPEUTIC DRUG MONITORING, 1998, 20 (05) :525-526